Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sensei Biotherapeutics Inc (SNSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SNSE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $67.5
1 Year Target Price $67.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.79% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.94M USD | Price to earnings Ratio - | 1Y Target Price 67.5 |
Price to earnings Ratio - | 1Y Target Price 67.5 | ||
Volume (30-day avg) 2 | Beta 0.1 | 52 Weeks Range 5.00 - 17.40 | Updated Date 06/30/2025 |
52 Weeks Range 5.00 - 17.40 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.14% | Return on Equity (TTM) -64.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -20182702 | Price to Sales(TTM) - |
Enterprise Value -20182702 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 1260400 | Shares Floating 827417 |
Shares Outstanding 1260400 | Shares Floating 827417 | ||
Percent Insiders 34.21 | Percent Institutions 7.69 |
Analyst Ratings
Rating 2 | Target Price 67.5 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sensei Biotherapeutics Inc
Company Overview
History and Background
Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on developing immunotherapies for cancer. Founded in 2011, it is headquartered in Boston, MA. The company's initial focus was on developing vaccines that target specific cancer antigens to stimulate an immune response. It evolved to focus on its Targeted Immunomodulatory Small Molecules (TIMSTM) platform.
Core Business Areas
- Drug Development: Focused on discovering and developing immunotherapies targeting cancer. Its primary focus is its TMIS platform to target the tumor microenvironment. They leverage the TMIS platform to develop therapeutic candidates to reprogram the tumor microenvironment.
Leadership and Structure
Sensei Biotherapeutics is led by an executive team with expertise in oncology drug development. The company is organized into research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- SNS-101: A conditionally active antibody targeting VISTA (V-domain Ig suppressor of T cell activation), an immune checkpoint protein. It's designed to block VISTA's immunosuppressive activity in the tumor microenvironment while minimizing systemic toxicity. Competitors developing VISTA-targeting therapies include Johnson & Johnson and GSK. SNS-101 is currently in Phase 1/2 clinical trials.
- SNS-VISTA ADC: An antibody-drug conjugate that targets VISTA. Preclinical stage. No market share data available yet. Potential competitors are companies developing ADCs in immuno-oncology.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing substantial growth driven by advances in understanding the tumor microenvironment and the immune system's role in cancer. Immune checkpoint inhibitors, cell therapies, and cancer vaccines are key segments.
Positioning
Sensei Biotherapeutics is positioned as a company specializing in novel immunotherapies, particularly those targeting the tumor microenvironment. Its TIMS platform aims to address limitations of existing immunotherapies.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of USD. Sensei is positioned to capture a portion of the TAM through development of novel therapeutics.
Upturn SWOT Analysis
Strengths
- Novel TIMS platform
- Experienced management team
- Proprietary VISTA-targeting antibodies
- Focus on tumor microenvironment modulation
Weaknesses
- Limited number of clinical-stage assets
- High cash burn rate
- Dependence on external funding
- Early stage of development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of TIMS platform to other targets
- Positive clinical trial results
- Increasing demand for novel immunotherapies
Threats
- Competition from established immuno-oncology companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- JNJ
- GSK
- MRTX
- NKTR
Competitive Landscape
Sensei Biotherapeutics faces intense competition from larger pharmaceutical companies with established immuno-oncology franchises. Sensei needs successful clinical trials and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Sensei Biotherapeutics has grown through raising capital and advancing its pipeline through preclinical and clinical development.
Future Projections: Future growth is dependent on positive clinical trial results and potential partnerships or acquisitions.
Recent Initiatives: Sensei Biotherapeutics is focused on advancing its clinical trials and exploring partnerships.
Summary
Sensei Biotherapeutics is a development-stage biopharmaceutical company with a promising platform in tumor microenvironment modulation. Success hinges on clinical trial outcomes, especially SNS-101. The company faces challenges regarding funding, strong competition, and regulatory hurdles. A successful clinical trial could prove the TMIS platform and offer considerable upside. Failure, or funding issues, could hurt shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise. This analysis is based on publicly available information and is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sensei Biotherapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2021-02-04 | President, CEO & Director Mr. John K. Celebi M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.senseibio.com |
Full time employees 14 | Website https://www.senseibio.com | ||
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.